To clarify: Blum repeated himself to emphasize that a Tirasemtiv partnership deal does not in any way rely on waiting for additional study results of the drug. That means that a partnership announcement could come at any time or be delayed depending on other factors than the study calendar.
Blum has publicly guided for an ALS partnership the last two years. He even said he was at the term sheet stage last year and then decided the terms were not good enough and did a mega dilutive financing increasing the share count from 77 to 203 mm shares outstanding fully diluted.
At some point he may deliver, but his credibility has taken a hit.
Chances are the partnering terms Blum is seeking will be realized only if the data is stellar. Thus my belief that a partner is more likely to sign on in 2014 several months after data is public.
Here is the Earning Call Transcript from Seeking Alpha:
"So getting a deal done is not predicated on having data from BENEFIT-ALS. I should make that very clear. Getting a deal done is not predicated on having data from BENEFIT-ALS and it is still very much our priority to get a deal done and that’s where I’m spending quite substantial amounts of my time."
Blums words. Maybe after two years this is for real. You never know, I never liked him.